SEARCH

SEARCH BY CITATION

References

  • Bickel P. E. (2002) Lipid rafts and insulin signaling. Am. J. Physiol. Endocrinol. Metab 282, E1E10.
  • Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D. and Rub U. (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249 (Suppl. 3), III/1III/5.
  • Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., Mathews P. M., Noble W., Matsuoka Y. and Duff K. (2003) Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J. Neurosci. 23, 56455649.
  • Camargo F., Erickson R. P., Garver W. S., Hossain G. S., Carbone P. N., Heidenreich R. A. and Blanchard J. (2001) Cyclodextrins in the treatment of a mouse model of Niemann–Pick C disease. Life Sci. 70, 131142.
  • Chandra S., Chen X., Rizo J., Jahn R. and Sudhof T. C. (2003) A broken alpha-helix in folded alpha-Synuclein. J. Biol. Chem. 278, 15 31315 318.
  • Chang T. Y., Reid P. C., Sugii S., Ohgami N., CruZ. J. C. and Chang C. C. (2005) Niemann–Pick type C disease and intracellular cholesterol trafficking. J. Biol. Chem. 280, 20 91720 920.
  • Chen L. and Feany M. B. (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657663.
  • Cole S. L., Grudzien A., Manhart I. O., Kelly B. L., Oakley H. and Vassar R. (2005) Statins cause intracellular accumulation of APP, beta-secretase cleaved fragments, and Abeta via an isoprenoid-dependent mechanism. J. Biol. Chem. 280, 18 75518 770.
  • Conway K. A., Harper J. D. and Lansbury P. T. Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 25522563.
  • Eckert G. P., Igbavboa U., Muller W. E. and Wood W. G. (2003a) Lipid rafts of purified mouse brain synaptosomes prepared with or without detergent reveal different lipid and protein domains. Brain Res. 962, 144150.
  • Eckert G. P., Kirsch C., Leutz S., Wood W. G. and Muller W. E. (2003b) Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 36, S136S143.
  • Eliezer D., Kutluay E., Bussell R. Jr and Browne G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 10611073.
  • Fortin D. L., Troyer M. D., Nakamura K., Kubo S., Anthony M. D. and Edwards R. H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24, 67156723.
  • Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. and Iwatsubo T. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160164.
  • German D. C., Liang C. L., Song T., Yazdani U., Xie C. and Dietschy J. M. (2002) Neurodegeneration in the Niemann–Pick C mouse: glial involvement. Neuroscience 109, 437450.
  • Gniadecki R. (2004) Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem. Biophys. Res. Commun. 320, 165169.
  • Gondre-Lewis M. C., McGlynn R. and Walkley S. U. (2003) Cholesterol accumulation in NPC1-deficient neurons is ganglioside dependent. Curr. Biol. 13, 13241329.
  • Hansen L. A. and Galasko D. (1992) Lewy body disease. Curr. Opin. Neurol. Neurosurg. 5, 889894.
  • Hartman T. (2005) Cholesterol and Alzheimer's disease: statins, cholesterol depletion in APP processing and Abeta generation. Subcell Biochem. 38, 365380.
  • Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V. M., Trojanowski J. Q., Mann D. and Iwatsubo T. (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277, 49 07149 076.
  • Hashimoto M., Hernandez-Ruiz S., Hsu L., Sisk A., Xia Y., Takeda A., Sundsmo M. and Masliah E. (1998) Human recombinant NACP/a-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799, 301306.
  • Hashimoto M., Hsu L. J., Rockenstein E., Takenouchi T., Mallory M. and Masliah E. (2002) a-Synuclein protects against oxidative stress via inactivation of the C-jun N-terminal kinase stress signaling pathway in neuronal cells. J. Biol. Chem. 277, 11 46511 472.
  • Hashimoto M., Rockenstein E., Crews L. and Masliah E. (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 4, 2136.
  • Hashimoto M., Rockenstein E., Mante M., Crews L., Bar-On P., Gage F. H., Marr R. and Masliah E. (2004) An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther. 11, 17131723.
  • Ho G. J., Hashimoto M., Adame A., Izu M., Alford M. F., Thal L. J., Hansen L. A. and Masliah E. (2005) Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. Neurobiol. Aging 26, 625635.
  • Hsu L., Mallory M., Xia Y., Veinbergs I., Hashimoto M., Yoshimoto M., Thal L., Saitoh T. and Masliah E. (1998) Expression pattern of the non-Ab component of Alzheimer's disease amyloid precursor protein (NACP/a-synuclein) during brain development. J. Neurochem. 71, 338344.
  • Hutter-Paier B., Huttunen H. J., Puglielli L., et al. (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44, 227238.
  • Irizarry M., Kim T., McNamara M., Tanzi R., George J., Clayton D. and Hyman B. (1996) Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889895.
  • Iwai A., Masliah E., Yoshimoto M., De Silva R., Ge N., Kittel A. and Saitoh T. (1994) The precursor protein of non-Ab component of Alzheimer's disease amyloid (NACP) is a presynaptic protein of the central nervous system. Neuron 14, 467475.
  • Iwai A., Yoshimoto M., Masliah E. and Saitoh T. (1995) Non-Ab component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34, 10 13910 145.
  • Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G. and Goedert M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26 29226 294.
  • Jo E., Fuller N., Rand R. P., St George-Hyslop P. and Fraser P. E. (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J. Mol. Biol. 315, 799807.
  • Johnson C. C., Gorell J. M., Rybicki B. A., Sanders K. and Peterson E. L. (1999) Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 28, 11021109.
  • Kilsdonk E. P., Yancey P. G., Stoudt G. W., Bangerter F. W., Johnson W. J., Phillips M. C. and Rothblat G. H. (1995) Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 270, 17 25017 256.
  • Klein U., Gimpl G. and Fahrenholz F. (1995) Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 34, 13 78413 793.
  • Kokubo H., Helms J. B., Ohno-Iwashita Y., Shimada Y., Horikoshi Y. and Yamaguchi H. (2003) Ultrastructural localization of flotillin-1 to cholesterol-rich membrane microdomains, rafts, in rat brain tissue. Brain Res. 965, 8390.
  • Kosaka K., Yoshimura M., Ikeda K. and Budka H. (1984) Diffuse type of Lewy body disease. Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree – A new disease? Clin. Neuropathol. 3, 183192.
  • Larbi A., Douziech N., Khalil A., Dupuis G., Gherairi S., Guerard K. P. and Fulop T. Jr (2004) Effects of methyl-beta-cyclodextrin on T lymphocytes lipid rafts with aging. Exp. Gerontol. 39, 551558.
  • Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T. and Lansbury P. T. Jr (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 10891102.
  • De Lau L. M., Bornebroek M., Witteman J. C., Hofman A., Koudstaal P. J. and Breteler M. M. (2005) Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64, 20402045.
  • Lee G., Tanaka M., Park K., Lee S. S., Kim Y. M., Junn E., Lee S. H. and Mouradian M. M. (2004) Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J. Biol. Chem. 279, 68346839.
  • Li H., Repa J. J., Valasek M. A., Beltroy E. P., Turley S. D., German D. C. and Dietschy J. M. (2005) Molecular, anatomical, and biochemical events associated with neurodegeneration in mice with Niemann–Pick type C disease. J. Neuropathol. Exp. Neurol. 64, 323333.
  • Loftsson T. and Masson M. (2001) Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm. 225, 1530.
  • Ma D. W., Seo J., Switzer K. C., Fan Y. Y., McMurray D. N., Lupton J. R. and Chapkin R. S. (2004) n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J. Nutr. Biochem. 15, 700706.
  • Maroteaux L., Campanelli J. and Scheller R. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 28042815.
  • Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 12651269.
  • McKeith I. G. (2000) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol. Clin. 18, 865902.
  • McLaurin J., Darabie A. A. and Morrison M. R. (2002) Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis. Ann. NY Acad. Sci. 977, 376383.
  • Michikawa M. (2003) The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol. Mol. Neurobiol. 27, 112.
  • Mori F., Hayashi S., Yamagishi S., Yoshimoto M., Yagihashi S., Takahashi H. and Wakabayashi K. (2002) Pick's disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus. Acta Neuropathol (Berl) 104, 455461.
  • Morishima-Kawashima M. and Ihara Y. (1998) The presence of amyloid β-protein in the detergent-soluble membrane compartment of human neuroblastoma cells. Biochemistry 37, 15 24715 253.
  • Mucke L., Abraham C., Ruppe M., Rockenstein E., Toggas S., Alford M. and Masliah E. (1995) Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP). J. Exp. Med. 181, 15511556.
  • Murphy D., Reuter S., Trojanowski J. and Lee V.-Y. (2000) Synucleins are developmentally expressed, and a-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 32143220.
  • Narayanan V. and Scarlata S. (2001) Membrane binding and self association of alpha-synucleins. Biochemistry 40, 99279934.
  • Ohtani Y., Irie T., Uekama K., Fukunaga K. and Pitha J. (1989) Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186, 1722.
  • Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P. and Haass C. (2000) Constitutive phosphorylation of the Parkinson's disease associated a-synuclein. J. Biol. Chem. 275, 390397.
  • Outeiro T. F. and Lindquist S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 17721775.
  • Pandur P. D., Dirksen M. L., Moore K. B. and Moody S. A. (2004) Xenopus flotillin1, a novel gene highly expressed in the dorsal nervous system. Dev. Dyn. 231, 881887.
  • Perrin R., Woods W., Clayton D. and George J. (2000) Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids: structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34 39334 398.
  • Perrin R. J., Woods W. S., Clayton D. F. and George J. M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41 95841 962.
  • Petrucelli L., Dickson D., Kehoe K., et al. (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703714.
  • Pitha J., Irie T., Sklar P. B. and Nye J. S. (1988) Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci. 43, 493502.
  • Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., Kagan B., Ghiso J. and Lal R. (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl Acad. Sci. USA 102, 10 42710 432.
  • Saito Y., Suzuki K., Hulette C. and Murayama S. (2004) Aberrant phosphorylation of alpha-synuclein in human Niemann–Pick type C1 disease. J. Neuropathol. Exp. Neurol. 63, 323328.
  • Salmon D., Hansen L., Masliah E., Galasko D., Butters N. and Katzman R. (1989) Neuropsychological characteristics of a Lewy body variant of Alzheimer's disease. Soc. Neurosci. Abstr. 15, 863.
  • Shaikh S. R., Cherezov V., Caffrey M., Stillwell W. and Wassall S. R. (2003) Interaction of cholesterol with a docosahexaenoic acid-containing phosphatidylethanolamine: trigger for microdomain/raft formation? Biochemistry 42, 12 02812 037.
  • Sharon R., Goldberg M. S., Bar-Josef I., Betensky R. A., Shen J. and Selkoe D. J. (2001) alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl Acad. Sci. USA 98, 91109115.
  • Sharon R., Bar-Josef I., Mirick G., Serhan C. and Selkoe D. (2003a) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J. Biol. Chem. 278, 49 87449 881.
  • Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. and Selkoe D. J. (2003b) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583595.
  • Shastry B. S. (2001) Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci. Res. 41, 512.
  • Sidhu A., Wersinger C. and Vernier P. (2004) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? Faseb J. 18, 637647.
  • Simons K. and Ikonen E. (1997) Functional rafts in cell membranes. Nature 387, 569572.
  • Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. and Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 64606464.
  • Spillantini M., Schmidt M., Lee V.-Y., Trojanowski J., Jakes R. and Goedert M. (1997) a-Synuclein in Lewy bodies. Nature 388, 839840.
  • Sudhof T. and Jahn R. (1991) Proteins of synaptic vesicles involved in exocytosis and membrane recycling. Neuron 6, 120.
  • Takahashi M., Kanuka H., Fujiwara H., Akihiko K., Hasegawa M., Miura M. and Iwatsubo T. (2003) Phosphorylation of a-synuclein characteristic of synucleinopathy lesions is recapitulated in a-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155158.
  • Takeda A., Hashimoto M., Mallory M., Sundsmo M., Hansen L., Sisk A. and Masliah E. (1998) Abnormal distribution of the non-Ab component of Alzheimer's disease amyloid precursor/a-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab. Invest. 78, 11691177.
  • Takenouchi T., Hashimoto M., Hsu L., Mackowski B., Rockenstein E., Mallory M. and Masliah E. (2001) Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human a-synuclein. Mol. Cell. Neurosci. 17, 141150.
  • Toggas S., Masliah E., Rockenstein E. and Mucke L. (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367, 188193.
  • Trojanowski J. and Lee V. (1998) Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55, 151152.
  • Ulmer T. S., Bax A., Cole N. B. and Nussbaum R. L. (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem. 280, 95959603.
  • Wakabayashi K., Takahashi H., Obata K. and Ikuta F. (1992) Immunocytochemical localization of synaptic vesicle-specific protein in Lewy body-containing neurons in Parkinson's disease. Neurosci. Lett. 138, 237240.
  • Walkley S. U. and Suzuki K. (2004) Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta 1685, 4862.
  • Wassall S. R., Brzustowicz M. R., Shaikh S. R., Cherezov V., Caffrey M. and Stillwell W. (2004) Order from disorder, corralling cholesterol with chaotic lipids. The role of polyunsaturated lipids in membrane raft formation. Chem. Phys. Lipids 132, 7988.
  • Weinreb P., Zhen W., Poon A., Conway K. and Lansbury P. J. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13 70913 715.
  • Wood W. G., Schroeder F., Igbavboa U., Avdulov N. A. and Chochina S. V. (2002) Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging 23, 685694.
  • Yanagisawa K. (2002) Cholesterol and pathological processes in Alzheimer's disease. J. Neurosci. Res. 70, 361366.
  • Yu W., Gong J. S., Ko M., Garver W. S., Yanagisawa K. and Michikawa M. (2005) Altered cholesterol metabolism in Niemann–Pick type C1 mouse brains affects mitochondrial function. J Biol Chem. 280, 11 73111 739.
  • Yunomae K., Arima H., Hirayama F. and Uekama K. (2003) Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 536, 225231.